M&A Deal Summary

Jazz Pharmaceuticals Acquires Cavion

On August 12, 2019, Jazz Pharmaceuticals acquired life science company Cavion for 313M USD

Acquisition Highlights
  • This is Jazz Pharmaceuticals’ 5th transaction in the Life Science sector.
  • This is Jazz Pharmaceuticals’ 5th largest (disclosed) transaction.
  • This is Jazz Pharmaceuticals’ 4th transaction in the United States.
  • This is Jazz Pharmaceuticals’ 1st transaction in Virginia.

M&A Deal Summary
Date 2019-08-12
Target Cavion
Sector Life Science
Buyer(s) Jazz Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 313M USD
Advisor(s) MTS Health Partners LP (Financial)
Cooley (Legal)

Target

Cavion

Charlottesville, Virginia, United States
Cavion, Inc. is a clinical-stage biotechnology company. Cavion's portfolio of T-type calcium channel modulators is being developed to restore the brain's natural rhythms in a variety of neurological diseases such as essential tremor, Parkinson's disease tremor, neuropathic pain, and epilepsy with absence seizures. Cavion, Inc. was founded in 2006 and is based in Charlottesville, Virginia.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Jazz Pharmaceuticals

Dublin, Ireland
Category Company
Founded 2003
Sector Life Science
Employees2,800
Revenue 3.8B USD (2023)
DESCRIPTION
Jazz Pharmaceuticals office in Palo Alto, California.
Jazz Pharmaceuticals office in Palo Alto, California.

Jazz Pharmaceuticals is a specialty biopharmaceutical company that identifies, develops, and commercializes products to address unmet medical needs in focused therapeutic areas. Jazz Pharmaceuticals was founded in 2003 and is based in Dublin, Ireland.

DEAL STATS #
Overall 5 of 6
Sector (Life Science) 5 of 6
Type (Add-on Acquisition) 5 of 6
State (Virginia) 1 of 1
Country (United States) 4 of 4
Year (2019) 1 of 1
Size (of disclosed) 5 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-05-31 Celator Pharmaceuticals

Ewing, New Jersey, United States

Celator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator's proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations of anti-cancer drugs, incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination after administration and ensuring exposure of this ratio to the tumor.

Buy $1.5B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-02-03 GW

Cambridge, United Kingdom

GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX® (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX® for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC.

Buy $6.7B
Mergr

Product

Company

Legal